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ABSTRACT: Human NEMO (NF-κB essential modulator) is
a 419 residue scaffolding protein that, together with catalytic
subunits IKKα and IKKβ, forms the IκB kinase (IKK)
complex, a key regulator of NF-κB pathway signaling.
NEMO is an elongated homodimer comprising mostly α-
helix. It has been shown that a NEMO fragment spanning
residues 44−111, which contains the IKKα/β binding site, is
structurally disordered in the absence of bound IKKβ. Herein
we show that enforcing dimerization of NEMO1−120 or
NEMO44−111 constructs through introduction of one or two
interchain disulfide bonds, through oxidation of the native Cys54 residue and/or at position 107 through a Leu107Cys mutation,
induces a stable α-helical coiled-coil structure that is preorganized to bind IKKβ with high affinity. Chemical and thermal
denaturation studies showed that, in the context of a covalent dimer, the ordered structure was stabilized relative to the
denatured state by up to 3 kcal/mol. A full-length NEMO-L107C protein formed covalent dimers upon treatment of mammalian
cells with H2O2. Furthermore, NEMO-L107C bound endogenous IKKβ in A293T cells, reconstituted TNF-induced NF-κB
signaling in NEMO-deficient cells, and interacted with TRAF6. Our results indicate that the IKKβ binding domain of NEMO
possesses an ordered structure in the unbound state, provided that it is constrained within a dimer as is the case in the
constitutively dimeric full-length NEMO protein. The stability of the NEMO coiled coil is maintained by strong interhelix
interactions in the region centered on residue 54. The disulfide-linked constructs we describe herein may be useful for
crystallization of NEMO’s IKKβ binding domain in the absence of bound IKKβ, thereby facilitating the structural
characterization of small-molecule inhibitors.
The cytoplasmic scaffolding protein NF-κB essentialmodulator (NEMO), also known as IκB kinase γ
(IKKγ), is a compelling but also a challenging target for drug
discovery.1 In complex with the catalytic IKKα and IKKβ
proteins, NEMO forms the active kinase IκB kinase (IKK),
which performs a key role in activating NF-κB pathway
signaling.2 IKK phosphorylates IκB and triggers its proteolytic
degradation, allowing transcription factor NF-κB to translocate
to the nucleus where it modulates expression of biological
effector genes.3,4 NF-κB pathway signaling is a major regulator
of many important biological processes, including cell
proliferation, cell survival, and elements of the immune
response, and is considered a drug target for a range of
pathologies including inflammation5 and several kinds of
cancer.6 A peptide derived from the NEMO binding domain
(NBD) of IKKβ has been used in multiple studies to show that
inhibition of the interaction of NEMO with IKKα/β can block
cytokine-induced NF-κB activation, NF-κB-dependent gene
expression and inflammation in animal models.7−10 Thus,
developing pharmaceutically useful inhibitors that bind to
NEMO and block its interaction with IKKα/β is of interest as a
therapeutic strategy.
Human NEMO is a 419 amino acid protein that contains five
main domains: helix 1 (HLX1, sometimes called “coiled-coil
1”), helix 2 (HLX2), a coiled-coil domain (CC), a leucine
zipper domain (LZ), and a C-terminal zinc finger (ZF), as
illustrated in Figure 1A. Although the stoichiometry of active
NEMO in vivo has been the subject of considerable
debate,11−14 most available data now point to a NEMO
homodimer as the primary functional form of the protein.15,16
There is strong evidence that the NEMO dimer adopts a highly
extended structure,14 and NEMO has been proposed to interact
with a number of various proteins at different sites along its
length.17−19 Although no crystal structure has yet been
reported for full-length NEMO, some of these interactions
have been characterized in atomic detail through generation of
X-ray cocrystal structures of the binding partner with a
fragment of NEMO (Figure 1B).16,20,21 In one such structure,
it was shown that the NEMO binding domain of IKKβ
(residues 701−745) interacts with the region of NEMO
extending from approximately residues 44−111, within the
Received: July 27, 2014
Revised: October 30, 2014
Published: November 15, 2014
Article
pubs.acs.org/biochemistry
© 2014 American Chemical Society 7929 dx.doi.org/10.1021/bi500920n | Biochemistry 2014, 53, 7929−7944
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
helix 1 domain.16 The structure shows that, in complex with a
44-mer peptide derived from IKKβ, NEMO44−111 exists as an α-
helical coiled coil that binds two molecules of IKKβ, one on
each face of the symmetric NEMO dimer (Figure 1B). We have
recently shown that interactions along the length of IKKβ701−745
contribute to NEMO binding. These studies confirmed and
extended previous reports by showing that IKKβ residues 734−
742 occupy the major binding energy hot spot on NEMO,7 and
identified two additional regions within IKKβ701−745 that are
critical for high affinity binding to NEMO.22
Despite interest in the NEMO/IKKβ interaction as a drug
target, several features of NEMO make drug discovery against
this site challenging. As a cytoplasmic protein, NEMO is not a
candidate for targeting with an antibody or other biopharma-
ceutical agent, and therefore must be targeted using a small-
molecule (i.e., synthetic organic) drug or other drug class that is
membrane permeable. Moreover, as a protein−protein
interaction (PPI), the IKKβ binding site on NEMO falls into
a class of drug targets that has been considered challenging for
small-molecule drug discovery.23−27 There are also obstacles to
obtaining a crystal structure of NEMO or the relevant IKKβ
binding domain of NEMO in an unbound state, which limits
the use of structure-based approaches in any drug discovery
effort. Although Rushe et al. were able to obtain a cocrystal
structure of NEMO44−111 with IKKβ701−745, they found that this
NEMO fragment was disordered in the absence of IKKβ
peptide and thus is not a good candidate for crystallization.16 In
contrast, we have recently reported evidence suggesting that
residues 44−111 of NEMO are not disordered in the context of
the full-length protein.15 Nevertheless, in the absence of a
means to crystallize full-length NEMO, the disorder in smaller
fragments containing the IKKβ binding domain presents an
obstacle to obtaining a crystal structure of this critical region of
NEMO in an unbound state, or to cocrystallizing NEMO with
small-molecule ligands to obtain information on their binding
modes.
Here we characterize the structure and stability of the IKKβ
binding domain of NEMO, and use biochemical and
biophysical approaches to investigate how the active coiled-
coil conformation of NEMO can be stabilized through
formation of appropriately positioned interchain disulfide
bonds. We demonstrate that covalent dimerization of
NEMO44−111 or NEMO1−120, either through oxidation of the
native cysteine at position 54 or by introduction of a cysteine at
position 107 through a Leu107Cys mutation, induces formation
of a coiled-coil structure that is stable in the absence of IKKβ
peptide. We quantify the degree of stabilization afforded by
interchain disulfide bonds at each of these two positions using
chemical and thermal denaturation, and show that the disulfide-
stabilized constructs are active for binding IKKβ. We further
show that, when expressed in mammalian cells, full-length
NEMO-L107C forms covalent dimers upon treatment of the
cells with H2O2, and that NEMO-L107C can bind endogenous
IKKβ and reconstitute NF-κB signaling in mammalian cells in
culture. Taken together, our results show that the IKKβ binding
region is natively ordered as a coiled coil within the NEMO
dimer, and identify noncovalent interactions in the region of
NEMO centered on Cys54 as a major contributor to coiled-coil
stability. Furthermore, the disulfide-stabilized constructs we
describe may enable crystallization of NEMO’s IKKβ binding
domain in the unbound state or with small-molecule inhibitors.
■ EXPERIMENTAL PROCEDURES
Construction of Bacterial and Retroviral Expression
Vectors. Bacterial expression of the NEMO1−120 and
NEMO44−111 constructs used the backbone vector pDEST-
His-SUMO containing an N-terminal 9xHis-SUMO tag
(Invitrogen, Carlsbad, CA). The human NEMO1−120 or
NEMO44−111 sequence together with an N-terminal tobacco
etch virus (TEV) cleavage site was cloned into this vector
through two rounds of PCR using the standard Gateway
cloning protocol. In the first round of PCR, the TEV cleavage
site was added to the N terminus of NEMO 1−120 or 44−111
using primers containing both the TEV cleavage site and a
partial NEMO sequence. A full-length human NEMO cDNA
containing cysteine-to-alanine mutations at positions 11, 76, 95,
131, and 16728 was used as a template. In the second round,
attB sites were added to both ends of the first round PCR
product using primers containing attB/attP sites. Primer
sequences are provided in the Supporting Information. All
PCRs were performed on an MJ Mini Personal Thermal Cycler
(Bio-Rad) using the following conditions: 95 °C for 1 min,
then 30 cycles of 95 °C for 30 s, 58 °C for 30 s, and 72 °C for
30 s, followed by 72 °C for 10 min at the completion of the
cycles, and then 4 °C until the run was stopped. A total volume
of 50 μL was used for PCRs, and reactions consisted of 37 μL
of water, 5 μL of DeepVent thermal buffer, 1 μL of DeepVent
polymerase (2.5 U/μL) (New England Biolabs), 1 μL of dNTP
(10 μM), 1 μL of template (50 ng/μL), 2.5 μL of forward
primer (10 μM), and 2.5 μL of reverse primer (10 μM). PCR
products were purified using the QIAquick PCR Purification
Figure 1. Domain structure of NEMO. (A) Schematic representation
of the structure of human NEMO, showing the named domains helix 1
(HLX1), helix 2 (HLX2), coiled-coil (CC), leucine zipper (LZ), and
zinc finger (ZF). Also shown are the locations of NEMO’s 11 cysteine
residues (identified by residue number above the cartoon), and of
Leu107 which we mutated to cysteine in some NEMO constructs. The
binding site locations for selected NEMO ligands are indicated by
colored bars under the cartoon. (B) Regions of NEMO that have been
characterized crystallographically: NEMO44−111 in complex with IKKβ
peptide (PDB: 3BRV);16 NEMO150−272 in complex with vFlip (PDB:
3CL3);20 NEMO252−336 in complex with diubiquitin (PDB: 2ZVN);
42
and NEMO397−417 (PDB: 2JVX).
58 Regions for which no structure has
been reported are shown as a string of dots (one dot per ∼5 amino
acids). Below is shown a close-up view of the 2:2 complex of
NEMO44−111 (green) with IKKβ701−745 (orange) from Rushe et al.
16
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Kit (Qiagen). The BP reaction was performed in a total volume
of 5 μL, which included 0.4 μL of pDONR221 (375 ng/μL),
3.6 μL of PCR product (70 ng/μL), and 1 μL of Gateway BP
Clonase II Enzyme mix. Samples were incubated at 25 °C for 1
h, and reactions were then quenched by adding 0.5 μL of
proteinase K and incubating at 37 °C for 10 min. Products were
transformed into DH5α competent cells, and colonies were
isolated on LB plates containing kanamycin (50 μg/mL).
Plasmids were purified from kanamycin-resistant colonies using
the QIAprep Spin Miniprep Kit (Qiagen), and were sequenced
to verify that the DNA sequences were inserted successfully
into pDONR221. The LR reaction was then performed in a
total volume of 5 μL, containing 1 μL of pDEST-His-SUMO
(100 ng/μL), 2 μL of pDONR221-target DNA (125 ng/μL), 1
μL of Gateway LR Clonase II Enzyme mix, and 1 μL of water.
Samples were incubated at 25 °C for 1 h, and reactions were
quenched by adding 0.5 μL proteinase K and incubating at 37
°C for 10 min. Products were transformed into DH5α
competent cells and transformed colonies were selected on
LB plates containing ampicillin (100 μg/mL). As above,
plasmids were purified by using the QIAprep Spin Miniprep Kit
(Qiagen) and sequenced to verify their integrity.
Retroviral vectors (in pBABE-puro) for expression of wild-
type and 7xAla NEMO have been described previously.15 The
pBABE vector for the expression of L107C was created by
PCR-based overlap mutagenesis to change Leu codon 107
(CTC) to Cys (TGC) in the 7xAla NEMO mutant vector. The
L107C change was confirmed by DNA sequencing. Details of
retroviral vector constructions can be found at www.nf-kb.org.
Site-Directed Mutagenesis. All codon changes in bacterial
expression vectors for NEMO were created using the following
procedures. First, PCR using mutant oligonucleotides was
performed under the following conditions: 95 °C for 1 min,
then 15 cycles of 95 °C for 30 s, 55 °C for 1 min, and 68 °C for
7 min, followed by 68 °C for 10 min at the completion of the
cycles, and then 4 °C until the run was stopped. Components
of the PCRs were as described above. After PCR, 1 μL of DpnI
was added and the samples were incubated at 37 °C for 3 h. A
volume of 5 μL of the reaction was then transformed into
DH5α competent cells. Plasmids with mutations were selected
and sequenced as described above.
Plasmid expression vectors for the expression of FLAG-
tagged 7xAla, 5xAla, and 7xAla/L107C NEMO were created by
subcloning PCR-amplified cDNA fragments into pcDNA-
FLAG with EcoRI and BamHI, as described previously for
wild-type pcDNA-FLAG-NEMO.28 pcDNA-HA-TRAF6 was
described previously.29
Protein Expression and Purification. For protein
expression, plasmids were transformed into T7 express
competent Escherichia coli BL21 (DE3) cells (New England
Biolabs) according to the manufacturer’s instructions, and
transformants were selected on LB plates containing ampicillin
(100 μg/mL). A single colony was used to inoculate 50 mL of
LB with ampicillin, and the culture was incubated at 37 °C
overnight with shaking. For large-scale expression, 1 L of LB
containing ampicillin was inoculated with 10 mL of the
overnight culture. Cells were grown at 37 °C to an OD600 of
0.4−0.6. To induce protein expression, IPTG was added to a
final concentration of 1 mM and cells were grown for an
additional 2 h. Then 2.5 g of cells were isolated by
centrifugation and were lysed using a microfluidizer in 50 mL
of lysis buffer containing 1 mM benzamidine, 1 mM PMSF, 0.1
mM EDTA, and 1 tablet of Roche protease inhibitor cocktail.
The cell lysate was centrifuged at 18000g for 15 min, and the
supernatant discarded, to leave a pellet containing cell debris
together with inclusion bodies containing the target protein.
The pellet was washed and suspended using wash buffer (lysis
buffer supplemented with 0.5% Triton X-100). The washed
inclusion body pellet was centrifuged as described above, and
the wash step was repeated with water to remove the Triton X-
100. Inclusion bodies were solubilized with 8 M Urea, by
pipetting repeatedly until the inclusion bodies were thoroughly
dissolved. This solubilization step can take as long as overnight
to maximize the inclusion body dissolution, and to give time for
full oxidation of cysteine thiols into disulfides. The denatured
target protein was refolded on a HisTrap HP 5 mL column and
purified. The on-column refolding and purification were
performed under the following conditions: 10 mL of dissolved
inclusion bodies was loaded onto the column, the bound
protein was refolded by washing the column with 20 column
volumes of a linear gradient of 8 M urea with nickel column
binding buffer (20 mM sodium phosphate pH 7.4, 500 mM
NaCl, 40 mM imidazole), and then the refolded protein was
eluted from the column with elution buffer (20 mM sodium
phosphate pH 7.4, 500 mM NaCl, 500 mM imidazole). Elution
of the protein was monitored by UV absorbance at 280 nm, and
the fractions containing protein were combined and concen-
trated using an Amicon Ultra-15 centrifugal filter unit according
to the manufacturer’s instructions. Protein was quantified by
absorbance at 280 nm using a NanoDrop 2000 instrument
(Thermo Scientific), using extinction coefficients calculated by
the ExPASy Proteomics Server.30
The 9xHis-SUMO fusion partner was removed using TEV
protease, as described previously.31 Briefly, the tagged proteins
were dialyzed into TEV reaction buffer (50 mM Tris-HCl pH
8.0, 0.5 mM EDTA and 1 mM DTT). TEV protease was added
to the 9xHis-SUMO-NEMO substrate at a ratio of 1:100, based
on O.D.280, and the reaction mixture incubated overnight at 4
°C. The product mixture was loaded onto a HisTrap HP 5 mL
column to separate the untagged NEMO from the cleaved
9xHis-SUMO fusion partner. The cleaved NEMO protein was
concentrated and dialyzed into 50 mM HEPES buffer. The
protein was flash frozen and stored at −80 °C. All variants were
analyzed by mass spectrometry to confirm the intact mass.
Samples were estimated to be >95% pure as determined by
SDS-PAGE. After removal of the fusion partner, the
NEMO44−111 constructs contained no tryptophan or tyrosine
and, therefore, had negligible absorbance at 280 nm. For these
proteins, the concentrations were measured at 205 nm in a 1
cm path length quartz cuvette, using an extinction coefficient
that was calculated from the amino acid sequence as
described.32 Quantifications were performed in triplicate.
All constructs containing cysteines at position 54 and/or 107
were found to exist as 100% covalent dimer after purification, as
shown by nonreducing SDS-PAGE, provided that sufficient
time was allowed during solubilization of the inclusion bodies
to ensure oxidation of free cysteines. For the constructs
containing cysteine at both positions 54 and 107, which would
migrate as a dimer in nonreducing SDS-PAGE even if only one
disulfide were present, full oxidation was demonstrated using
the colorimetric thiol reagent 5,5′-dithio-bis(2-nitrobenzoic
acid) (DTNB). To prepare 100% monomeric forms of the
cysteine-containing constructs, the protein was incubated
overnight at 4 °C with 25 mM DTT in 6 M urea. The urea
was removed by buffer exchange, using an Amicon column, into
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a storage buffer for monomeric protein of 50 mM HEPES
buffer containing 25 mM DTT.
DTT Reduction Tolerance Test. To assess each
construct’s tolerance to DTT, NEMO1−120 proteins at a
concentration of 100 μM were incubated in water containing
25 mM DTT at 4 °C for various periods of time, and then
analyzed by SDS-PAGE without boiling. To determine whether
the protein could be reduced under denaturing conditions, 100
μM of protein was incubated with 25 mM reducing agent
(TCEP or DTT) with or without 6 M urea at room
temperature for 1 h. Samples were then analyzed by SDS-
PAGE together with a control sample that was boiled in
reducing buffer containing 100 mM DTT. To determine the
DTT concentration required to reduce Cys54-containing
NEMO dimers under denaturing conditions, NEM-
O1−120(des3C/C54) was incubated for 1 h at room temperature
with 6 M urea plus various concentrations of DTT.
Circular Dichroism Spectroscopy. CD spectra were
measured using an Applied Photophysics CS/2 Chirascan
instrument with a 1 mm path length quartz cuvette at a scan
speed of 2 nm/s. Unless otherwise indicated, spectra were
measured at 10 μM NEMO protein (based on NEMO
monomer) in sodium phosphate at pH 7.4 at 25 °C. The
buffer background was subtracted. The measured ellipticity in
millidegrees (θ) was converted to mean residue ellipticity
([θ]MRE) using the following equation:
θ θ= Cnl[ ] /(10 )MRE (1)
where C is the molar concentration, n is the number of
residues, and l is the path length in cm. The CD spectra in
water and phosphate buffer were found to be identical, and so
the results were combined and treated as replicates. Three
independent measurements were conducted for each NEMO
sample. The percent α-helix content was determined by
comparing the [θ]MRE at 222 nm measured after 2 h of
incubation at room temperature in aqueous buffer (20 mM
phosphate, pH 7.4) with that measured in 97% 2,2,2-
trifluoroethanol (TFE), using the equation below:
θ
θ
α‐ = ×helix (%) (aqueous)
(TFE)
100222
222 (2)
Urea-Induced Denaturation Studies. NEMO protein
was incubated at 25 °C for at least 1 h with freshly prepared
urea solution diluted to different concentrations, in 20 mM
phosphate, pH 7.4, before CD measurement of mean residue
ellipticity at 222 nm as described above. Preliminary measure-
ments showed no difference in denaturation curves when the
protein was incubated for 1 or 24 h, indicating that an
incubation time of 1 h was sufficient to reach equilibrium. To
determine whether the denaturation was reversible, identical
samples of 100 μM NEMO1−120(des4C/L107C) were treated
either with 4 M urea to ensure complete denaturation, or with
water as a control. After 1 h at 25 °C, each sample was diluted
10-fold into water. After 30 min of refolding, CD spectra were
taken. There was no difference between the urea treated group
after refolding and water treated group (Figure S1, Supporting
Information), indicating denaturation was fully reversible.
Denaturation data were fitted by nonlinear least-squares
analysis to a two-state model containing additional terms to
capture the effect of urea on the measured ellipticity of the fully
folded and fully unfolded protein, as described.33,34 The
equation used for fitting was:
θ =
+ + +
+
− −
− −
Δ
Δ
y m y m
[ ]
( [urea]) ( [urea]) e
1 e
222 MRE
f f u u
( )
( )
G
RT
m
RT
G
RT
m
RT
H2O [urea]
H2O [urea]
(3)
where yf and mf are the intercept and slope of the urea
dependence of [θ222]MRE for the fully folded protein, yu and mu
are the corresponding intercept and slope of the fully unfolded
protein, ΔGH2O is the free energy of unfolding at zero urea, m is
the slope of the unfolding transition region, R is the molar gas
constant, and T is absolute temperature. This model was used
because the urea denaturation curves for NEMO1−120(des4C/
L107C) and for the corresponding NEMO44−111 construct
showed a positive linear slope at urea concentrations above the
level required for full denaturation of the protein, indicating
that in these cases urea has a small but significant effect on the
ellipticity of the fully denatured protein. Fitting the
denaturation curves for these constructs to the above equation
while allowing mu to have a small positive value gave a better fit
to the data. For the other disulfide-stabilized constructs,
allowing mu to have a nonzero value had no significant effect
on the curve fits or the values of the parameters ΔGH2O or m
that were obtained from the fitting; for the monomeric
constructs NEMO1−120(des4C) and NEMO44−111(des3C), a
value for mu of ∼0 was clearly preferred. In no case was a
nonzero value for mf indicated, and so this parameter was fixed
at zero for all data fits. Thus, only for NEMO1−120(des4C/
L107C) and NEMO44−111(des3C/L107C) was a pretransition
or post-transition slope allowed, with a positive value for mu
being allowed in these two cases. For the monomeric constructs
NEMO1−120(des4C) and NEMO44−111(des3C), the value of yf,
the ellipticity corresponding to fully folded protein, was poorly
defined by the experimental data because the protein was <50%
folded even at zero urea. Therefore, in fitting the data for these
two constructs, we fixed the yf at the mean value observed for
the other three constructs in the series, based on the
assumption that the fully folded state would have an α-helical
content similar to that seen for the native states of the other
constructs of the same length. For all denaturation experiments
we found that measurements made at the lowest and highest
urea concentrations (zero and 7.76 M urea) were variable and
frequently anomalous, and therefore data for these extreme
urea concentrations were excluded from fitting in all cases.
To linearize the denaturation data, for the purpose of more
clearly illustrating the extrapolation to zero urea, we calculated
the free energy of unfolding, ΔG, at each urea concentration
using the following equation,
θ
θ
Δ = −
−
−
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟G RT
y
y
ln
[ ]
[ ]
f 222 MRE
222 MRE u (4)
where the minimum and maximum ellipticities, yf and yu, are
the values determined for each construct from the nonlinear
regression analysis using eq 5. ΔG was then plotted against urea
concentration to generate the linear plots.
Thermal Denaturation Studies. Proteins, at a concen-
tration of 10 μM in 20 mM phosphate, pH 7.4, were heated
from 5 to 90 °C at a rate of 2.5 °C/min, using the internal
temperature control function of the CD spectrometer. Spectra
from 180 to 260 nm were taken at a scanning rate of 0.5 s/nm.
No obvious difference in melting curves was seen when the
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slower ramping rate of 1 °C/min was used, suggesting that the
selected rate was appropriate. Thermal denaturation was
completely reversible, as demonstrated by comparing the CD
spectra NEMO1−120(des4C/L107C) before and after thermal
denaturation and refolding (Figure S2, Supporting Informa-
tion). The melting temperature Tm for each protein was
estimated from the maximum of a plot of the first derivative of
θ222 was against temperature. Each result represents the average
of two independent experiments.
Fluorescence Anisotropy Binding Assay. All bacterially
expressed NEMO variants were characterized by measuring
their binding affinities with IKKβ peptide (residues 701−745)
in a direct binding format using fluorescence anisotropy (FA)
as described previously.15,22 Assays were performed in 96-well
nontreated black polystyrene plates (Corning Costar), using a
SpectraMax M5 microtiter plate reader (Molecular Devices,
Sunnyvale, CA). For each experiment, 50 μL of water, 50 μL of
4× TNT buffer (200 mM Tris, 800 mM NaCl, 0.04% Triton X-
100, 4 mM DTT, pH 7.5), 50 μL of N-terminally FITC-labeled
IKKβ peptide (60 nM), and 50 μL of NEMO protein at varying
concentrations were added to each well to give final
concentrations of 15 nM FITC-IKKβ in 50 mM Tris, 200
mM NaCl, 0.01% Triton X-100, 1 mM DTT, pH 7.5 in a total
volume of 200 μL. The plates were incubated on a plate shaker
(UltraCruz shaker for microplates, Santa Cruz Biothechnology)
for 1 h at 250 rpm, and were then incubated at 25 °C for 5 min
before fluorescence was measured. Samples were read by
excitation at 488 nm and emission at 520 nm in high sensitivity
mode. Values were the averages of 100 measurements for each
well, and each experiment was done in duplicate. After
background subtraction the anisotropy values, A, were fitted
by nonlinear least-squares regression to the modified quadratic
binding equation shown below:15
= + −
×
+ + − + + −
⎪ ⎪
⎪ ⎪⎧⎨
⎩
⎫
⎬
⎭
A A A A
K K
( )
[R] [L] ([R] [L] ) 4[R] [L]
2[L]
0 max 0
T D T T D T
2
T T
T
(5)
where A0 is the anisotropy observed for unbound FITC-IKKβ,
Amax is the maximum anisotropy signal at saturating [NEMO],
[R]T and [L]T are the total concentrations of NEMO protein
and FITC-IKKβ, and KD is the binding affinity. When fitting
the binding data for the monomeric constructs NEM-
O1−120(des4C) and NEMO44−111(des3C), the value of Amax
was fixed at the average value observed for the three disulfide-
stabilized constructs in the same series.
Mammalian Cell Culture and Transfection. A293T cells
and NEMO-deficient mouse fibroblasts were grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Life Tech-
nologies, Grand Island, NY) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Biologos, Montgomery,
IL) and penicillin−streptomycin as described.15,28 A293T cells
were transfected with plasmids for expression of FLAG-tagged
NEMO or HA-tagged TRAF6 proteins using the polyethyle-
nimine (PEI) method as described previously.28 Retrovirus
stocks for the expression of NEMO proteins were prepared by
cotransfecting BOSC23 packaging cells as described previ-
ously.15,28 After infection, retrovirally transduced NEMO-
deficient fibroblasts were selected with 1 μg/mL puromycin
(Sigma, St. Louis, MO).
Western Blotting and Co-Immunoprecipitation. West-
ern blotting was performed as described previously.15 For the
analysis of FLAG-NEMO proteins from transfected A293T
cells, whole-cell extracts were prepared in AT buffer (20 mM
HEPES, pH 7.9, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
20 mM Na4P2O7, 1 mM DTT, 1% v/v Triton X-100, 20% w/v
glycerol, 1 mM Na3VO4, 1 μg/mL PMSF, 1 μg/mL leupeptin, 1
μg/mL pepstatin). Samples containing approximately equal
amounts of protein were then boiled in SDS-sample buffer
(0.625 M Tris, pH 6.8, 2.3% w/v SDS, 10% w/v glycerol) with
or without 5% β-mercaptoethanol. For analyzing H2O2-induced
NEMO dimerization, transfected A293T cells were treated with
0.2 or 1 mM H2O2 for 10 min and samples were lysed directly
in SDS sample buffer without β-mercaptoethanol. For analyzing
total NEMO or phosphorylated IκBα, retrovirally transduced
NEMO deficient cells were treated with 20 ng/mL TNFα
(R&D Systems, Minneapolis, MN) for 10 min and then lysed
directly in SDS sample buffer containing 5% β-mercaptoetha-
nol. Samples containing approximately equal amounts of
protein were then analyzed by Western blotting with anti-
NEMO antiserum (#2685, Cell Signaling Technology, Danvers,
MA; 1:1000 dilution) or anti-phospho-IκBα antiserum (#9246,
Cell Signaling Technology; 1:1000 dilution). In all cases, the
primary antibody−antigen complexes were detected with
horseradish peroxidase-labeled secondary antiserum and Super-
signal Dura West chemiluminescence (Thermo Scientific).
Co-immunoprecipitation experiments on transfected A293T
cells were performed as described previously.15 Briefly, cells in
35-mm tissue culture dishes were lysed in 200 μL of AT buffer.
An aliquot (5 μL) was saved as the input sample. A 100 μL
aliquot of the lysate was immunoprecipitated with 30 μL of
anti-M2 FLAG agarose beads (cat #A2220; Sigma, St. Louis,
MO). After washing, bound proteins were removed by heating
the beads for 10 min at 90 °C in SDS sample buffer containing
β-mercaptoethanol. Samples (input or immunoprecipitate)
were then analyzed by reducing SDS-PAGE followed by
Western blotting with anti-FLAG (cat #2368; Cell Signaling
Technology, Danvers, MA), anti-IKKβ (sc-7607; Santa Cruz
Biotechnology), or anti-HA (sc-805; Santa Cruz Biotechnol-
ogy; 1:500) antiserum, as described above.
TNFα-induced Cell Death Assays. NEMO-deficient
mouse fibroblasts reconstituted with 7xAla NEMO or 7xAla/
L107C NEMO were treated with 50 ng/mL TNFα (R&D
Systems) for 18 h, and the number of live cells was determined
using a crystal violet-based cell viability assay, as described
previously.15,28
■ RESULTS
Protein Design, Expression, and Purification. NEMO
fragment 44−111 has previously been reported to be
structurally disordered in the absence of bound IKKβ peptide.16
Our attempts to design a stabilized form of the IKKβ binding
domain of NEMO were guided by two hypotheses. One
hypothesis was that a substantially longer NEMO construct,
encompassing residues 1−120 would generate additional
noncovalent interactions sufficient to stabilize the dimeric
coiled-coil structure seen in the bound complex with IKKβ. The
second hypothesis was that covalent dimerization through one
or two appropriately positioned disulfide bonds would induce a
stable coiled-coil. The first 120 residues of NEMO contain four
cysteine residues, at positions 11, 54, 76, and 95 (Figure 1A).
We have previously shown that none of these cysteines is
required for the IKKβ binding activity of full-length NEMO,
either in vitro or in cells.15 Therefore, in designing constructs
containing specific, interchain disulfide bonds, we changed all
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other cysteine residues to alanine, to eliminate the possibility of
disulfide-linked aggregation or non-native disulfide bonding
and thereby facilitate the generation of structurally homoge-
neous proteins. Figure 2A shows that, of the three cysteines in
the structurally characterized region of NEMO encompassing
residues 44−111, Cys76 and Cys95 are positioned such that
they cannot participate in interchain disulfide bonds in the
IKKβ-bound conformation of the protein. Cys54, on the other
hand, appears well positioned to form a disulfide bond cross-
linking the two NEMO monomers that form the coiled coil
(Figure 2B). The distance between the two Cys54 β carbons is
4.3 Å, within the range of 3−6 Å required for disulfide bonds in
proteins.35 We therefore designed a construct, NEM-
O1−120(des3C/C54), in which cysteines 11, 76, and 95 were
changed to alanine but Cys54 was retained, to allow us to test
the effect of a single interchain disulfide at position 54 on the
structure and properties of NEMO1−120, compared to a second
construct, NEMO1−120(des4C), in which all four native
cysteines (11, 54, 76, and 95) were changed to alanine.
The most important region of NEMO for binding IKKβ lies
roughly between residues 89 and 104,22 some distance from
Cys54. Therefore, we wished to determine whether introduc-
tion of an interchain disulfide closer to the 89−104 region
would stabilize the structure of this key part of the IKKβ
binding domain. Examination of the cocrystal structure of
NEMO44−111 with IKKβ701−745 showed that Leu107 is
positioned such that mutation to cysteine should allow
formation of an interchain disulfide bond with minimal
disruption of the polypeptide backbone conformation (Figure
2C). We therefore made a third construct, NEMO1−120(des4C/
L107C), in which all four native cysteines were changed to
alanine, and a cysteine was introduced at position 107. Finally,
we created a fourth construct that contained both the native
Cys54 and the L107C mutation, designated NEM-
O1−120(des3C/C54/L107C), to test the effect of interchain
disulfide bonds at both of these positions on the structure and
stability of NEMO1−120. The structures of these four
NEMO1−120 constructs are shown schematically in Figure 2D.
To enable us to distinguish effects due to construct length from
effects due to the introduction of interchain disulfide bonds,
we created a corresponding set of mutants based on the
minimal IKKβ binding region NEMO-44−111, designated
NEMO44− 1 1 1 (de s3C) , NEMO44− 1 1 1 (de s2C/C54) ,
NEMO44−111(des3C/L107C), and NEMO44−111(des2C/C54/
L107C) (Figure 2D).
The NEMO constructs described above were expressed in
bacteria as SUMO fusion proteins containing an N-terminal
9xHis tag for affinity purification and a tobacco etch virus
(TEV) cleavage site between the SUMO domain and the first
NEMO residue (Figure 2D). The SUMO fusion partner was
used to improve expression and to provide additional bulk to
facilitate analysis of NEMO protein binding properties by
fluorescence anisotropy (FA). The TEV site was designed such
that removal of the 9xHis-SUMO fusion partner with TEV
protease left only three non-native amino acids (Gly-Ser-Gly)
at the N terminus of the NEMO protein. The proteins were
expressed in E. coli, resolubilized from inclusion bodies under
denaturing conditions in 8 M urea, and refolded on a Ni/NTA
metal ion affinity column before being eluted from the column
with an imidazole gradient. Analysis of the products by SDS-
PAGE showed that, with the exception of NEMO1−120(des4C)
and NEMO44−111 (des3C) which contain no cysteines, all
constructs purified as covalent dimers, and could be reduced to
monomers of the expected size by boiling in 100 mM DTT for
5 min (Figure 3A). The 9xHis-SUMO fusion partner was
removed by incubation of the purified fusion constructs with
TEV protease, followed by removal of the cleaved 9xHis-
SUMO fragment by passage over a Ni/NTA metal ion affinity
column, as described in Experimental Procedures (Figure 3B−
D). Notably, constructs containing Cys54 were highly resistant
to reduction under native conditions. For example, treatment of
the cleaved NEMO1−120(des3C/C54) with 25 mM DTT at 4
°C achieved only ∼50% reduction even after 3 weeks
Figure 2. Design of disulfide-stabilized NEMO constructs. (A)
NEMO44−111 from the structure by Rushe et al.
16 (IKKβ peptide not
shown). The locations of the cysteine residues at positions 54, 76, and
95 are highlighted in red; Leu107 is shown in blue. (B) Close-up of
the region around Cys54, showing that these cysteines are well
positioned to form an interchain disulfide bond. (C) Close-up of
region around Leu107, showing that the β-carbons are positioned such
that cysteine residues introduced through L107C mutation would be
suitably positioned to form an interchain disulfide bond.59 (D)
Schematic representation of the eight NEMO constructs made in the
current work. The TEV cleavage site is indicated by a red triangle. The
identities of the residues present at positions 54, 76, 95, and 107 (and
at position 11 for the NEMO1−120 proteins) are indicated for each
construct using the single letter code for the amino acid.
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(Figure 3B), with NEMO1−120(des3C/C54/L107C) showing
even less reduction under similar conditions. Either boiling or
denaturant (urea) was required in addition to DTT to
completely reduce the dimer (Figure 3C). Even under
denaturing conditions, 25 mM DTT or TCEP was required
to reduce Cys54-containing constructs within 1 h (Figure 3D).
In contrast, NEMO1−120(L107C) was readily reduced by DTT
even in the absence of urea (Figure 3B).
Introduction of Interchain Disulfides Induces In-
creased α-Helical Structure in NEMO. To test the
hypothesis that the NEMO N-terminal domain α-helical
coiled-coil can be stabilized by the inclusion of all residues
from 1 to 120 or by covalent dimerization through
appropriately placed disulfides, we characterized the structure
and stability of the eight NEMO constructs shown in Figure 2D
using circular dichroism (CD) spectrometry, after removal of
the 9xHis-SUMO tag with TEV protease. The α-helical content
was quantified by comparison to the spectrum obtained for the
same construct in 97% 2,2,2-trifluoroethanol (TFE), a solvent
which favors α-helix formation,36,37 as shown in Figure S3
(Supporting Information). Fully reduced, monomeric NEM-
O1−120(des3C/C54) gave a CD spectrum indicating only 37%
α-helical structure (Figure 4A), identical to the helical content
of NEMO1−120(des4C) which contains no cysteines (Table 1).
These values are similar to the 32% α-helical content seen with
the monomeric construct NEMO44−111(des3C) (Table 1),
suggesting that extension of this shorter fragment to include
residues 1−43 and 112−120 was not sufficient to stabilize a
coiled-coil structure. In contrast, CD analysis of the same
construct in the oxidized state, which is a covalent dimer due to
an interchain disulfide bond at position 54, showed a
substantial increase in α-helical content to 60% (Figure 4A).
NEMO1−120 containing an engineered interchain disulfide at
position 107 (NEMO1−120(des4C/L107C)) or containing
disulfides at both positions 54 and 107 (NEMO1−120(des3C/
C54/L107C)) similarly showed 60−70% α-helical content
(Table 1). In the shorter NEMO44−111 constructs, the presence
of disulfide bonds at positions 54 and/or 107 increased α-
helical content to an even greater degree, with the values
ranging from 75 to 88% α-helix depending on the construct
(Figures S3 and S4, Supporting Information and Table 1).
In the published X-ray crystal structure of NEMO44−111 with
IKKβ701−745, amino acids 44−48 and 111 are not visible in the
structure, suggesting that these terminal residues are substan-
tially disordered or mobile. The residual GSG tripeptide left at
the N termini of our constructs after TEV cleavage presumably
also is disordered. Thus, for the NEMO44−111 constructs
adoption of the conformation seen in the crystal structure
would correspond to 60 residues of α-helix out of 70 residues
total = 86% α-helix content. Thus, the level of α-helix content
observed for the three disulfide-stabilized NEMO44−111
constructs, shown in Table 1, is consistent with the nearly
complete adoption of the active conformation of the protein
that was seen crystallographically.16 For the longer NEMO1−120
constructs, adoption of a fully α-helical structure between
residues 50 and 108, with the remainder of the protein being
disordered, would correspond to an α-helix content of 49% (60
out of 123 residues). The extent of α-helix content observed for
the disulfide-stabilized forms of NEMO1−120 thus indicates that
an additional dozen or so of the ∼60 residues outside the
immediate IKKβ binding region are also α-helical in these
constructs. This interpretation is consistent with the observa-
tion that a fraction of NEMO1−120(des4C) spontaneously
adopts an α-helical structure even as a monomer. Taken
together, the above results show that enforcing covalent
dimerization via an interchain disulfide bond at position 54
Figure 3. Analysis of NEMO constructs by SDS-PAGE. (A) SDS-
PAGE analysis showing that NEMO1−120(des4C) and NEM-
O44−111(des3C) purify as monomers, while the other cysteine
containing NEMO1−120 and NEMO44−111 constructs as isolated are
predominantly covalent dimers that can be reduced to monomers by
boiling under reducing, denaturing conditions. (B) Susceptibility of
the NEMO1−120 proteins to reduction with 25 mM DTT after removal
of the 9xHis-SUMO fusion partner using TEV protease. The cleaved
products were treated with 25 mM DTT in water at 4 °C for various
times, and then analyzed by SDS-PAGE without boiling. The C54
containing constructs are highly resistant to reduction under
nondenaturing conditions, whereas the construct containing only a
single disulfide at position 107 is readily reduced. The result shown is
representative of two independent experiments. (C) SDS-PAGE
analysis showing that TEV-cleaved NEMO1−120(des3C/C54) can be
reduced by 25 mM DTT or TCEP (1 h at room temperature) under
denaturing conditions. (D) SDS-PAGE analysis (without boiling) of
TEV-cleaved NEMO1−120(des3C/C54) incubated with various con-
centrations of DTT, decreasing from 25 mM in 2-fold dilutions, in 6
M urea for 1 h at room temperature, showing that 25 mM DTT is
required to reduce NEMO1−120(des3C/C54) even under denaturing
conditions.
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and/or position 107 stabilizes a conformation of NEMO that is
largely α-helical in the IKKβ binding region extending roughly
from residues 50−108, but that the protein outside of this
region remains largely unstructured especially in the longer,
NEMO1−120 constructs.
Disulfide-Stabilized NEMO Constructs Show In-
creased Binding Affinity for IKKβ. To determine whether
the increased α-helical content of the disulfide-stabilized
NEMO constructs described above is due to stabilization of
the active α-helical coiled-coil conformation seen crystallo-
graphically for NEMO44−111 bound to IKKβ701−745 peptide,
16
we tested the ability of each protein to bind FITC-labeled
IKKβ701−745. FITC-IKKβ701−745 has been shown previously to
bind to both full-length NEMO22 and to truncated NEMO
constructs that contain the NEMO N-terminal domain.16 For
these measurements, we used the FA binding assay that we
have described previously.22 In this assay, a fixed concentration
of 15 nM FITC-IKKβ701−745 is incubated with various
concentrations of NEMO protein. The binding affinity can be
determined by plotting total anisotropy versus NEMO
concentration and fitting to the appropriate quadratic or
hyperbolic binding equation.15,38 We used the intact 9xHis-
SUMO fusion proteins for these initial measurements to
maximize the reduction in tumbling rate of the labeled peptide
upon binding, so as to ensure a robust change in anisotropy.
We initially measured the binding of FITC-IKKβ701−745 to
the four NEMO1−120 constructs. We also compared the binding
activity of NEMO1−120(des3C/C54) as a covalent dimer versus
as a fully reduced monomer, so as to directly test the
consequences for activity of the presence or absence of an
interchain disulfide bond in the same construct. The results
show that the monomeric forms of NEMO1−120 bound
IKKβ701−745 with only micromolar affinity, but the forms
stabilized by interchain disulfide bonds at positions 54 and/or
107 bound 6−30-fold more strongly (Figure 5A, Table 1). A
similar pattern of activities was seen for the NEMO44−111
constructs des3C, des3C/L107C, and des2C/C54/L107C
(des2C/C54 was not tested) (Figure S5A, Supporting
Information). To make sure that the binding activities of the
constructs were not influenced by the presence of the 9xHis-
SUMO we repeated the measurements with the NEMO1−120
constructs after removal of the fusion partner. The results
showed that the presence of the fusion partner had no
significant effect on the binding properties of the constructs
(Figure S5B, Supporting Information). Taken together, these
results indicate that the disulfide-stabilized forms of NEMO are
active, and that covalent dimerization preorganizes the
polypeptide in a conformation that confers relatively high
affinity binding with IKKβ.
Interchain Disulfide Bonds Increase the Resistance of
NEMO to Chemical and Thermal Denaturation. To assess
the effect of covalent dimerization on the stability of the α-
helical structure of NEMO, we performed chemical and
thermal denaturation experiments on the NEMO constructs
using CD to monitor loss of secondary structure. A decrease in
mean residue ellipticity at 222 nm (θ222) indicates a decrease in
α-helical content.39 These measurements were done using the
TEV-cleaved NEMO constructs to avoid interference from the
presence of the 9xHis-SUMO fusion partner. Preliminary time-
course measurements showed that the extent of denaturation
attained its equilibrium value within 1 h, leading us to choose
an incubation period of 1 h for subsequent experiments. As
shown in Figure 5B, all four NEMO1−120 constructs were
completely denatured by 8 M urea at 25 °C. However, at lower
concentrations of urea they showed different degrees of
denaturation. NEMO1−120(des4C), which contains no cysteine
and thus cannot form covalent dimers, was highly sensitive to
denaturant. Indeed, the CD analysis showed that NEM-
O1−120(des4C) is <50% ordered even in the absence of urea.
NEMO1−120(des3C/C54) and NEMO1−120(des4C/L107C)
showed [urea]50 values of 1.5−2.0 M, indicating that the
Figure 4. Effect of interchain disulfide bonds on NEMO secondary
structure. (A) Overlaid CD spectra in 20 mM phosphate, pH 7.4,
showing that fully reduced, monomeric TEV-cleaved NEM-
O1−120(des3C/C54) possesses only modest α-helix content (dotted
line), whereas the oxidized form of the same construct, containing an
interchain disulfide bond at position 54, possesses a substantially α-
helical structure (solid line). Spectra shown are representative of two
independent experiments. (B) Overlaid CD spectra (20 mM
phosphate, pH 7.4) showing the relative α-helical content of the
four TEV-cleaved NEMO1−120 constructs shown in Figure 2D.
NEMO1−120(des3C/C54) (blue), NEMO1−120(des4C/L107C)
(green) and NEMO1−120(des3C/C54/L107C) (red) are present in
their oxidized, covalent dimer forms. The spectrum of the monomeric
NEMO1−120(des4C) is shown in black. Spectra shown are
representative of three independent experiments. Corresponding
data for the NEMO44−111 constructs are shown in Figure S4
(Supporting Information). (C) CD spectra showing that NEM-
O1−120(des4C), which in aqueous buffer is largely disordered (solid
line), adopts an α−helical structure in 97% TFE (dotted line). Spectra
shown are representative of two independent experiments. Spectra for
all eight constructs are shown in Figure S3, and the measured values
for mean residue elipticity at 222 nm are provided in Table S1
(Supporting Information).
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Table 1. Structure, Stability, and Binding Affinities of the NEMO Constructs from Figure 2D
KD (nM)
NEMO variant α-helix (%)a [urea]50 (M)
b slope (m) (cal/M)b ΔGH2O (kcal/mol)
c Tm (°C)
d taggede untaggedf
NEMO1−120
des4C 37 ± 5 <0 330 ± 20 −0.2 ± 0.02 27 ± 2 1.900 ± 100 1500 ± 400
des3C/C54g 60 ± 1 1.9 ± 0.9 390 ± 60 0.7 ± 0.2 33 ± 2 70 ± 9 120 ± 70
des4C/L107Cg 61 ± 7 1.5 ± 0.3 1500 ± 130 2.3 ± 0.2 45 ± 2 310 ± 30 240 ± 90
des3C/C54/L107Cg 72 ± 8 4.3 ± 0.5 720 ± 40 3.0 ± 0.2 67 ± 4 180 ± 20 80 ± 40
NEMO44−111
des3C 32 ± 3 <0 320 ± 20 −0.4 ± 0.02 24 ± 2 5600 ± 240 n.d.h
des2C/C54g 75 ± 4 2.3 ± 0.9 290 ± 40 0.6 ± 0.2 34 ± 3 n.d. n.d.
des3C/L107Cg 88 ± 23 1.4 ± 0.2 1900 ± 110 2.7 ± 0.2 43 ± 2 210 ± 20 n.d.
des2C/C54/L107Cg 83 ± 15 4.2 ± 0.8 670 ± 70 2.8 ± 0.2 70 ± 2 560 ± 50 n.d.
aPercent α-helix content, determined by comparing CD spectra measured in aqueous buffer versus in 97% TFE. Values are the average ± SD from
three independent experiments. bConcentration of urea required to give 50% denaturation at 25 °C, and slope value (m) for the denaturation curve,
determined through nonlinear regression analysis of urea denaturation curves measured in three independent experiments. Errors are standard errors
from the fit of the averaged data. cFree energy of unfolding extrapolated to [urea] = 0 M, determined through nonlinear regression analysis of urea
denaturation curves measured in three independent experiments. Errors are standard errors from the fit of the averaged data. dMelting temperature,
determined from CD melting curves. Values are the average Tm from two independent experiments ± the larger of half the difference or 2 degrees.
eAffinity for binding to FITC-IKKβ701−745, measured by fluorescence anisotropy using the 9xHis-SUMU-tagged constructs. Values are the best fit for
a single experiment performed in duplicate; errors are the Standard Errors for the curve fits. fAffinity for binding to FITC-IKKβ701−745, measured by
fluorescence anisotropy using the untagged NEMO1−120 constructs generated by removal of the fusion partner using TEV protease. Values are the
best fit for averaged data from three independent experiments; errors are the standard errors for the curve fits of the averaged data. gCovalent dimers
due to interchain disulfide bond(s) at positions 54 and/or 107. hn.d.: Not done.
Figure 5. Structural stability and binding affinity for IKKβ. (A) Binding affinity of the 9xHis-SUMO-tagged NEMO1−120(des4C) (black circles),
-(des3C/C54) (blue squares), -(des4C/L107C) (green triangles), and -(des3C/C54/L107C) (red lozenges) for FITC-IKKβ701−745, measured by
fluorescence anisotropy. The solid lines represent the best fit to a quadratic binding equation, as described in Experimental Procedures. Results show
the averages of duplicate measurements, with the error bars showing the spread between the duplicate values. The corresponding data for the tagged
NEMO44−111 constructs are shown in Figure S5A, and for the TEV-cleaved NEMO1−120 constructs in Figure S5B (Supporting Information). (B,C)
Urea denaturation curves for the TEV-cleaved NEMO1−120 constructs and NEMO44−111 constructs, respectively, as measured by CD (20 mM
phosphate, pH 7.4). The solid lines represent the best fit to a two-state denaturation equation, as described in Experimental Procedures. The curve
fits for NEMO1−120(des4C/L107C) and NEMO44−111(des3C/L107C) contain an extra term to account for the effect of urea on the observed
ellipticity of the fully denatured protein (see text). Plotted are average values from three independent experiments; error bars are standard deviations.
The [urea]50, slope (m), and ΔGu values obtained from the curve fits are collected in Table 1. (D) Thermal denaturation of the TEV-cleaved
NEMO1−120 constructs, monitored by the change in θ222 measured by CD (in 20 mM phosphate, pH 7.4). Colors are as in (A). Inset shows the first
derivative of the melting curve to illustrate how Tm was determined. Data shown are representative of two independent experiments. The
corresponding data for the NEMO44−111 constructs are shown in Figure S7 (Supporting Information). In panels (A)−(D) the cysteine-containing
constructs are present in their oxidized, covalently dimeric form.
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presence of a single interchain disulfide bond at position 54
substantially stabilized the protein. The presence of two
disulfides, at 54 and 107, resulted in additional stabilization,
as shown by NEMO1−120(des3C/C54/L107C) which gave a
[urea]50 value of 4.3 ± 0.5 M. In comparing the denaturation
curves for NEMO1−120(des3C/C54) and NEMO1−120(des4C/
L107C), it is notable that the construct containing the
engineered Cys107 has a much steeper slope than that
containing only the native Cys54.
We analyzed the urea denaturation curves to determine the
free energy of unfolding of each variant extrapolated to zero
urea, ΔGH2O, by fitting the results to a two-state unfolding
model (eq 3, Experimental Procedures) using nonlinear
regression (Figure 5B).33,34 This analysis is valid only if
denaturation is reversible. We therefore tested reversibility by
incubating NEMO1−120(des4C/L107C) in 4 M urea for 1 h,
conditions which fully denature this construct (Figure 5B), and
then diluting the protein 10-fold into aqueous buffer to give a
final urea concentration of 0.4 M. The CD spectrum of the
renatured protein was indistinguishable from that of a protein
sample that was treated identically in the absence of urea
(Figure S1, Supporting Information), showing that urea
Figure 6. Activity of full-length NEMO-L107C in vivo. A293T cells were transfected with expression vectors for the indicated FLAG-tagged NEMO
proteins or an empty vector (A−C). (A) Whole-cell extracts were prepared in AT buffer and samples were boiled in the presence (+) or absence (−)
of β-mercaptoethanol (βMe). Samples were then analyzed by anti-FLAG Western blotting. The positions of FLAG-NEMO monomers and dimers
(FLAG-NEMO2) are indicated. (B) Cells were treated with the indicated concentrations of H2O2 for 10 min and whole-cell extracts were prepared
directly in SDS-sample buffer lacking βMe. Western blotting was then performed as in (A). Shorter (top) and longer (bottom) exposures of the
same blot are shown to allow for visualization of the increase in L107C dimer with H2O2 treatment (upper image) and the dose-dependent
dimerization of wild-type NEMO (bottom image). (C) Extracts from cells transfected with the indicated FLAG-tagged NEMO proteins were
immunoprecipitated with anti-FLAG beads (IP: FLAG) and then Western blotted for either IKKβ (top) or FLAG-NEMO (bottom). The lanes
marked Input include 5% of the extract used in the immunoprecipitation. (D) NEMO-deficient mouse fibroblasts were transduced with retroviral
vectors for the indicated NEMO proteins or the corresponding empty vector. To confirm NEMO protein expression, extracts were subjected to anti-
NEMO Western blotting (top panel). Cells were also treated (+) with 20 ng/mL of TNFα for 10 min and extracts were subjected to Western
blotting for phospho-IκBα (middle panel). For the bottom graph, cells were treated with 50 ng/mL TNFα for approximately 18 h, and the number
of viable cells was quantified by crystal violet staining. % Cell Viability is percentage of viable cells after TNFα treatment as compared to the parallel,
untreated cultures. Values are the averages of three experiments performed with triplicate samples, with the indicated standard deviations. (E) A293T
cells were cotransfected with expression vectors for HA-TRAF6 and for the indicated FLAG-tagged NEMO proteins or an empty vector. The
identity of the NEMO constructs is as follows: w.t., wild-type NEMO; 7xAla, NEMO in which the seven cysteine residues at positions 11, 54, 76, 95,
131, 167, and 347 have each been mutated to Ala; 5xAla, NEMO in which the five cysteine residues at positions 11, 76, 95, 131, and 167 are mutated
to Ala, such that Cys54 and Cys347 are retained; L107C, 7xAla NEMO in which the additional mutation L107C has been introduced. The 7xAla and
5xAla NEMO constructs have been described previously.15 Extracts from cells were immunoprecipitated with anti-FLAG beads (IP: FLAG) and then
Western blotted for either HA-TRAF6 (top) or FLAG-NEMO (bottom). The identity of the HA-TRAF6 protein was confirmed by anti-TRAF6
Western blotting [not shown]. The lanes marked Input include ∼5% of the extract used in the immunoprecipitation.
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denaturation of the protein was fully reversible. Analysis of the
denaturation curves showed that the monomeric NEMO1−120
construct containing no cysteines is largely denatured even in
the absence of urea, with ΔGH2O < 0 at 25 °C (Table 1). The
presence of a single interchain disulfide at position 54 stabilized
the folded state to give ΔGH2O = 0.7 ± 0.2 kcal/mol, while the
engineered disulfide at position 107 achieved a greater
stabilization of 2.3 ± 0.2 kcal/mol. The NEMO1−120 construct
containing disulfides at both 54 and 107 was the most stable,
with ΔGH2O = 3.0 ± 0.2 kcal/mol. The denaturation behavior of
the NEMO44−111 constructs was essentially identical to that
seen for the longer NEMO constructs, both qualitatively
(Figure 5C) and quantitatively (Table 1). The denaturation
data for the NEMO1−120 and NEMO44−111 were also plotted in
a linearized form, as shown in Figure S6 (Supporting
Information), and showed good linearity, further validating
the use of a two-state unfolding model.
We also characterized the stability of the NEMO variants in
response to thermal denaturation. We monitored the structure
of each protein by CD using ellipticity at 222 nm measured
while slowly increasing the temperature of the sample from 5 to
90 °C. As shown in Figure 5D, the NEMO 1−120 variants
showed a range of melting temperatures. NEMO1−120(des4C)
gave a melting temperature of Tm = 27 ± 2 °C, consistent with
this monomeric construct being <50% structured at room
temperature. The presence of a single disulfide at either
position 54 or 107 substantially stabilized the proteins, resulting
in Tm values of 33 and 45 °C, respectively. The construct
containing two disulfides was highly stable to thermal
denaturation, melting only at 67 ± 4 °C. The thermal stabilities
of the NEMO44−111 constructs were also measured, and gave
similar results to those seen with the longer NEMO1−120
proteins (Table 1 and Figure S4, Supporting Information).
The L107C Mutation Can Mediate Covalent Dimeriza-
tion of Full-Length NEMO, and Does Not Affect NEMO’s
Ability to Activate NF-κB Signaling and Bind to TRAF6 in
Cells. We have previously shown that Cys54 can engage in
interchain disulfide bonding to form a covalent NEMO dimer
in the context of full-length NEMO protein,15,28 but that the
presence or absence of a disulfide at Cys54 does not affect the
binding affinity for IKKβ because full-length NEMO is
constitutively dimeric even when fully reduced in vivo.15 The
structural and functional consequences of introducing a
cysteine at position 107 into full-length NEMO have not
previously been investigated, however. To gain additional
evidence that the L107C mutation we introduced into the
NEMO1−120 and NEMO44−111 constructs does not compromise
the protein’s function, we introduced the L107C change into
full-length NEMO and evaluated the activity of this construct in
a range of cellular assays. The L107C change was made in the
7xAla NEMO background to allow us to evaluate disulfide
formation at position 107 without interference from the
cysteines present in wild-type protein at positions 54 and
347, which can mediate covalent dimerization of NEMO in
vivo.15,28 We have previously shown that the 7xAla NEMO
mutant can fully restore NF-κB signaling when expressed in
NEMO-deficient mouse fibroblasts.15 First, we determined
whether a cysteine at position 107 can mediate interchain
disulfide bond formation in full-length NEMO in cells. FLAG-
tagged versions of wild-type, 7xAla, and 7xAla/L107C NEMO
were expressed in A293T cells and the protein’s propensity to
form disulfide mediated dimers was assessed in two ways: (1)
by the formation of dimers post-lysis in the presence of
molecular oxygen, and (2) by the formation of dimers when
intact cells were treated with hydrogen peroxide. We have
shown previously that exposure of cell lysates to molecular
oxygen can induce NEMO dimer formation in a Cys54/347-
dependent fashion.28 Therefore, we lysed cells overexpressing
the relevant NEMO proteins under oxidizing conditions and
then analyzed NEMO protein by Western blotting under
reducing (plus β-mercaptoethanol) or nonreducing (no β-
mercaptoethanol) conditions. As shown in Figure 6A, wild-type
NEMO and 7xAla/L107C NEMO (but not 7xAla NEMO)
were converted to covalent dimers when cells were lysed under
these nonreducing conditions, and these dimers were reduced
to monomers by treatment of the lysates with SDS sample
buffer containing β-mercaptoethanol before SDS-PAGE.
Similarly, treatment of intact cells with H2O2 induced wild-
type and 7xAla/L107C NEMO, but not 7xAla NEMO, to form
covalent dimers (Figure 6B). Indeed, we generally found that
the L107C mutant formed disulfide-bonded dimers more
efficiently than wild-type NEMO under both conditions.
To assess the ability of L107C NEMO to participate in NF-
κB signaling, we conducted three experiments. First, by
coimmunoprecipitation using anti-FLAG beads, we found that
overexpressed FLAG-7xAla/L107C NEMO could interact with
endogenous IKKβ in A293T cells, as could FLAG-tagged wild-
type and 7xAla NEMO (Figure 6C). Second, NEMO-deficient
fibroblasts were retrovirally transduced with 7xAla or 7xAla/
L107C NEMO, or a control vector containing no gene. Cells
were then treated with TNFα for 10 min to measure
phosphorylation of IκBα or for 18 h to assess the ability of
the given NEMO protein to protect cells from TNFα-induced
cell death. Cells expressing either 7xAla or 7xAla/L107C
NEMO showed an increase in phospho-IκBα in response to 10
min treatment with TNFα (Figure 6D, middle), whereas
control cells showed no phospho-IκBα in the presence or
absence of TNFα. Moreover, 7xAla NEMO and 7xAla/L107C
NEMO both restored the ability of the NEMO-deficient cells to
survive when treated with TNFα for 18 h, whereas transduction
with an empty retroviral vector did not protect these cells
(Figure 6D, bottom). Activation of the NF-κB pathway in
response to TNFα requires that NEMO interact not only with
IKKβ through its N-terminal domain, but also with IκB through
NEMO’s C-terminal zinc finger domains40,41 and (non-
covalently) with di-Ubiquitin through NEMO’s central CoZi
domain.42 NEMO has also been shown to interact with E3
ligase TRAF6 for activation of a variety of downstream
signaling pathways that are important for normal cell function,
and several human disease mutations specifically affect the
NEMO-TRAF6 interaction.43,44 Therefore, as an additional
measure of NEMO activity, we assessed the ability of our Cys
mutant NEMO proteins to interact with TRAF6. As shown in
Figure 6E, all NEMO Cys mutants (7xAla, 5xAla [7xAla +
C54/347], and 7xAla/L107C) interacted with TRAF6 as
efficiently as wild-type NEMO, as measured by coimunopre-
cipitation from transfected A293T cells. Thus, the functional
assay shown in Figure 6D provides evidence that 7xAla/L107C
NEMO retains the ability to productively interact with key
binding partners at sites up and down its length.
Taken together, these results demonstrate that a cysteine at
residue 107 of NEMO can participate in disulfide formation in
the context of full-length NEMO when expressed in
mammalian cells, and that the L107C mutation does not affect
the ability of NEMO to functionally interact with IKKβ, IκB,
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diubiquitin or TRAF6 or to activate productive NF-κB signaling
in mammalian cells.
■ DISCUSSION
In this work we tested the hypothesis that the N-terminal
domain of NEMO possesses a stable coiled-coil structure in the
dimeric state, where dimer formation is induced either by the
introduction of interchain disulfide bonds or by noncovalent
interactions between NEMO polypeptides of sufficient length.
The results show that enforcing dimerization through one or
two appropriately positioned disulfide bonds results in
essentially full ordering of the α-helical coiled-coil region
between approximately residues 50 and 108, which constitutes
the IKKβ binding region of NEMO. This induced ordering
preorganizes this region of NEMO for binding IKKβ, as shown
by the accompanying enhancement in IKKβ binding affinity. In
contrast, NEMO residues 1−50 appear to be largely disordered
in both bound and unbound states. The finding that enforcing
dimerization of the NEMO IKKβ binding domain induces a
stable α-helical coiled coil supports our previous proposal that
the IKKβ binding region of NEMO is ordered in the context of
the full-length protein, which is constitutively dimeric.15
An interesting feature of our findings is that the presence of
an interchain disulfide bond at position 54 versus position 107
appears to stabilize the active, coiled-coil conformation of
NEMO to different extents. Constructs containing a single
disulfide at position 54 were relatively easy to denature, but
were exceptionally difficult to reduce, whereas constructs
containing a single disulfide at position 107 were more difficult
to denature but easier to reduce. The resistance to reduction of
NEMO molecules containing Cys54 suggests that a disulfide at
this position is buried within a relatively extensive and intimate
contact interface, thereby restricting access by the reducing
agent. Examination of the published X-ray crystal structure of
NEMO44−111 in complex with IKKβ701−745 indicates that the
interaction between the NEMO polypeptides is close and
relatively extensive in the vicinity of Cys54, as compared to the
much less intimate contact in the region of Leu107 (Figure
7).16 There is minimal direct interaction between the NEMO
monomers outside of these two localized contacts (Figure 7C).
The greater free energy of unfolding with NEMO1−120(des4C/
L107C) and NEMO44−111(des3C/L107C), compared to the
constructs containing only a disulfide at Cys54, is consistent
with this interpretation. Denaturation of the constructs
containing a single disulfide at position 107 involves disruption
of the intimate contact between the NEMO monomers in the
vicinity of amino acid 54, while the presence of a disulfide at
position 54 presumably locks this region together such that
denaturation involves primarily the disruption of only the
weaker interaction around Leu107. This interpretation also
accounts for the different slopes of the urea denaturation curves
for the constructs with a single disulfide at position 107 versus
position 54. According to the widely used Transfer Model for
protein denaturation,45 the degree of cooperativity observed in
chemical denaturation experiments, represented by the slope
factor m in eq 3, reflects the extent to which the solvent-
exposed surface area of the protein increases upon denatura-
tion.46,47 Thus, the large slopes seen for the proteins containing
only a disulfide at 107 indicates that denaturation is
accompanied by a large increase in solvent-exposed surface
area relative to the other constructs. We therefore conclude that
the difference in denaturation behavior and ease of reduction
between the NEMO constructs containing a single disulfide at
position 54 versus 107 derives from a close and favorable
contact between NEMO monomers in the region centered on
residue 54, which remains strong even when Cys54 is changed
to alanine. The large denaturation energy seen in the construct
containing disulfides at both of these positions likely has a
Figure 7. Regions of contact at the NEMO−NEMO interface, from
the published cocrystal structure of NEMO44−111 in complex with
IKKβ(701−745) (PDB code 3BRV).16 (A) Cys54 (colored yellow) is
largely buried at the center of an extensive and intimate contact
interface between the two NEMO monomers, one of which is shown
in surface representation and the other as a wire-frame. (B) Much
poorer contact is apparent in the vicinity L107 (colored magenta). (C)
Corresponding representation of the whole of NEMO44−111, showing
that the regions shown in panels (A) and (C) represent the only
points of direct contact in this domain of the NEMO dimer.
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different explanation, presumably reflecting the fact that the
denatured state in a doubly cross-linked NEMO dimer is highly
constrained and compact, and benefits from only a fraction of
the entropy gain that accompanies denaturation of the singly
cross-linked forms. Note that full-length NEMO, though
constitutively dimeric, does not have interchain disulfides in
the normal reducing environment of the cell15,28 and, therefore,
the presence of a cysteine that can be oxidized at position 54 to
form a disulfide in the dimer interface is unlikely to play a major
role in NEMO function under normal cellular conditions.
Our results additionally provide quantitative insight into the
energetics of coiled-coil formation in the IKKβ binding domain
of NEMO, as illustrated in Figure 8. The binding of monomeric
NEMO44−111(des3C) to IKKβ can notionally be separated into
two steps: (1) association of two disordered monomers to form
an ordered noncovalent coiled-coil dimer, with free energy
ΔGDimeriz, and (2) binding of two IKKβ molecules to this
noncovalent dimer to form the final complex. The self-
association of NEMO monomers can be further subdivided into
three notional steps. 1(a) Colocalization of the monomers into
close proximity, with an energetic cost equal to the configura-
tional entropy cost of colocalizing two molecules from a 1 M
standard state such that their translational and overall rotational
motions are coupled (ΔSConfig). 1(b) Adoption of a fully α-
helical structure separately by each monomer, with an energy
cost for each corresponding to the inverse of the free energy of
unfolding, ΔGH2O, for NEMO44−111(des3C). 1(c) Interaction of
the two α-helical monomers to form a noncovalent, coiled-coil
dimer, with the release of interaction energy ΔGInteract. If the
hypothetical preorganized noncovalent NEMO44−111 dimer is
assumed to bind IKKβ with a similar affinity to that observed
for the disulfide-stabilized NEMO44−111 covalent dimers, then
the 20-fold difference in IKKβ binding affinity between dimer
(step 2) and monomer (labeled as step 3 in Figure 8) implies
that ΔGDimeriz is small (−RT ln20 = 1.8 kcal/mol). Given that
ΔSConfig is known to be a large number (6−12 kcal/mol48−53)
and ΔGH2O is negative, the noncovalent interaction energy
between NEMO44−111 monomers, ΔGInteract, must be consid-
erable. Specifically, to account for the 6−30-fold difference in
IKKβ binding affinity, the NEMO monomers must interact
sufficiently strongly that approximately (1/30)−(1/6) = ∼3−
15% of the NEMO protein exists as dimer at the concentration
of 0.1−1 μM at which binding is seen in our assays. Thus, even
the relatively small NEMO fragments we use here appear to
show some tendency to preassociate, presumably mediated by
close and energetically favorable contacts in the vicinity of
residue 54. The interaction affinity is low, however, and
therefore under the conditions of our experiments the
constructs lacking any interchain disulfide bonds are largely
monomeric, consistent with the previously published NMR
data for NEMO44−111.
16 The ∼35% α-helix content we observed
with these constructs therefore presumably reflects mostly
adventitious helix formation within a monomeric polypeptide.
The observation that the shorter NEMO44−111(des3C) binds
IKKβ approximately as strongly as the longer NEM-
O1−120(des4C) confirms that regions outside residues 44−111
do not significantly contribute to NEMO self-association or to
IKKβ peptide binding. The energy diagram for the longer,
NEMO1−120 constructs should therefore look essentially
identical to that shown in Figure 8, as the additional residues
present in these longer constructs do not contribute to IKKβ
binding and remain largely disordered even in the bound state.
Although a wide range of values have been reported for the
binding affinity of NEMO for IKKβ,15,16,22,54,55 studies using
full-length NEMO in conjunction with IKKβ701−745 peptide
indicate an affinity for this interaction in the single digit
nanomolar range.22 It is noteworthy that even our disulfide-
stabilized, constitutively dimeric N-terminal domain constructs
of NEMO showed affinities that are ∼10-fold larger than that
observed for the full-length protein. There are several possible
reasons for this difference. It is unlikely that the lower affinity
results from the Cys-to-Ala changes at positions 76 or 95,
because we have previously shown that these changes in full-
length NEMO do not affect binding affinity for IKKβ701−745.
15
Figure 8. Energetic relationship between NEMO−NEMO interaction
and coiled-coil formation in NEMO44−111. The binding of monomeric
NEMO44−111(des3C) to IKKβ can notionally be separated into two
steps: (1) association of two disordered monomers to form an ordered
noncovalent coiled-coil dimer, with free energy ΔGDimeriz, and (2)
binding of two IKKβ molecules to this noncovalent dimer to form the
final complex. The self-association of NEMO monomers can be
further subdivided into three notional steps. 1(a) colocalization of the
monomers into close proximity (represented by a dashed red circle),
where ΔSConfig is the configurational entropy cost of colocalizing two
molecules from a 1 M standard state such that their translational and
overall rotational motions are coupled. 1(b) adoption of a fully α-
helical structure separately by each monomer, with an energy cost for
each corresponding to the inverse of the free energy of unfolding,
ΔGH2O, for NEMO44−111(des3C). 1(c) Interaction of the two α-helical
monomers to form a noncovalent, coiled-coil dimer, with the release of
interaction energy ΔGInteract. If the hypothetical preorganized non-
covalent NEMO44−111 dimer is assumed to bind IKKβ with a similar
affinity to that observed for the disulfide-stabilized NEMO44−111
covalent dimers, then the 20-fold difference in IKKβ binding affinity
between dimer (Step 2) and monomer (Step 3) implies that ΔGDimeriz
is small (−RT ln20 = 1.8 kcal/mol). Given that ΔSConfig is known to be
a large number (6−12 kcal/mol, see text) and ΔGH2O is negative, the
noncovalent interaction energy between NEMO44−111 monomers,
ΔGInteract, must be considerable. The energy diagram for the longer,
NEMO1−120 constructs would look essentially identical to that shown
here, as the additional residues present in these longer constructs do
not contribute to IKKβ binding and remain largely disordered even in
the bound state.
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However, one possibility is that, notwithstanding our careful
selection of the disulfide locations, the positioning of the
disulfides in our constructs is not fully compatible with high
affinity binding of IKKβ. We consider this explanation unlikely,
however, for two reasons. We have previously shown that
oxidation of Cys54 does not affect the binding affinity of full-
length NEMO for IKKβ,15 and we show here that introduction
of the L107C mutation into full-length NEMO did not affect its
ability to bind IKKβ, IκB, diubiquitin, or TRAF6 or to mediate
TNFα-induced activation of NF-κB in cells. Furthermore, the
ability of the full-length NEMO 7xAla/L107C protein to form a
covalent dimer upon treatment of cells with H2O2 supports our
hypothesis that these residues are appropriately positioned in
the native structure to form an interchain disulfide bond.
Moreover, it is unlikely that attenuation of IKKβ binding
affinity of such similar magnitude would occur with two
disulfides at such different locations within the NEMO
structure. Nevertheless, even small differences in structure
resulting in conformational or dynamic constraints on the
NEMO structure could account for a difference in binding
affinity of the magnitude that we observed, and therefore, we
cannot rule out this possibility. An alternative explanation for
the discrepancy in binding affinities between our constructs and
full-length NEMO is that regions of the NEMO sequence
downstream of the N-terminal 120 residues are required for
maximal IKKβ binding affinity.
One practical consequence of our results is to enable the
identification of forms of the NEMO N-terminal domain that
would be amenable to crystallization in the unbound state, or
cocrystallization with small molecules identified in screens for
inhibitors of the IKKβ binding site on NEMO.56 In the absence
of conditions for crystallizing full-length NEMO or larger
fragments that contain the IKKβ binding domain, cocrystall-
izing compounds with only the IKKβ binding region itself, as
was done with IKKβ701−745,
16 would appear to be the best
option. However, the high degree of disorder that these
workers demonstrated for the NEMO44−111 in the absence of
IKKβ peptide suggested that crystallization of unbound
NEMO44−111 would not be possible. Nor is it likely that a
weak-binding small molecule occupying a small portion of the
IKKβ binding site would stabilize an ordered NEMO structure
in the same way that the 45-mer IKKβ peptide does. Our
results show that the IKKβ binding region of NEMO can be
induced to adopt a stable coiled-coil structure in the absence of
ligand, by introduction of an interchain disulfide bond at
position 54 and/or position 107, and that the resulting,
rigidified proteins are compatible with IKKβ binding and NF-
κB signaling in vivo. Given the large number of single amino
acid changes along the length of NEMO that are associated
with human disease,57 we find it surprising that a NEMO
protein with eight scattered amino acid changes (as in L107C))
retains normal activity. However, we have only looked at the
ability of the 7xAla and L107C NEMO mutant proteins to
support signaling to NF-κB in response to TNFα, and to bind
to TRAF6. Therefore, we cannot rule out the possibility that
other activities are defective in these NEMO mutants.
Our results also suggest that the regions of NEMO between
approximately residues 1 and 44 are disordered in our
NEMO1−120 constructs both in the bound and unbound state.
In the published crystal structure of NEMO44−111 in complex
with IKKβ701−745 electron density could be resolved only for the
residues from residues 49 to 110,16 suggesting that a few
additional residues could also be dispensed with. Given the
strong correlation between structural order and the prospects
for obtaining protein crystals that diffract with high resolution,
our results suggest that our shorter, disulfide-stabilized
constructs NEMO44−111(des2C/C54), NEMO44−111(des3C/
L107C) and NEMO44−111(des2C/C54/L107C), or versions
of these constructs that are further truncated to remove a small
number of amino acids at the N terminus, are good candidates
for crystallization in an unbound state, and for cocrystallization
with inhibitors.
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